Conflict of interest statement: There are no conflicts of interest.175. South Asian J Cancer. 2018 Apr-Jun;7(2):151-155. doi: 10.4103/sajc.sajc_125_18.Practical consensus recommendations on ovarian suppression in early breast cancer(adjuvant).Singhal M(1), Sahoo TP(2), Aggarwal S(3), Singhvi A(4), Kaushal V(5), Rajpurohit S(6), Parthasarthi KM(7), Vora A(8), Ganvir M(3), Gupta S(9), Parikh PM(10).Author information: (1)Department of Medical Oncology, Indraprastha Apollo Hospital, New Delhi,India.(2)Department of Medical Oncology, Chirayu Cancer Hospital, Bhopal, MadhyaPradesh, India.(3)Department of Medical Oncology, Sir Ganga Ram Hospital, New Delhi, India.(4)Department of Medical Oncology, Choitram Hospital, Indore, Madhya Pradesh,India.(5)Department of Radiation Oncology, RCC, Rohtak, Haryana, India.(6)Department of Medical Oncology, RGCI, New Delhi, India.(7)Department of Medical Oncology, Dharamshila Cancer Hospital, New Delhi, India.(8)Department of Medical Oncology, Hope Clinic, New Delhi, India.(9)Department of Medical Oncology, Tata Memorial Center, Mumbai, Maharashtra,India.(10)Department of Oncology, Shalby Cancer and Research Institute, Mumbai,Maharashtra, India.Substantial survival benefits exist for patients with early-stage breast cancerwho undergo treatment with single-modality ovarian suppression, but its value is uncertain. Expert oncologist discussed to determine whether additional benefitsexist with ovarian suppression plus multiple adjuvant therapy which provides anew treatment option that reduces the risk of recurrence in early breast cancer. This expert group used data from published literature, practical experience andopinion of a large group of academic oncologists to arrive at this practicalconsensus recommendations for the benefit of community oncologists.DOI: 10.4103/sajc.sajc_125_18 PMCID: PMC5909295PMID: 29721484 